사이토메드 테라퓨틱스(GDTC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.95 (+12.30%), 시가총액 $0.01B, 52주 범위 $0.72 ~ $2.69.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the p
사이토메드 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사이토메드 테라퓨틱스의 현재 주가는 $0.95 (+12.30%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사이토메드 테라퓨틱스의 시가총액은 약 $0.01B입니다.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysi